MY195824A - A Pharmaceutical Composition for Treating Gastrointestinal Diseases - Google Patents

A Pharmaceutical Composition for Treating Gastrointestinal Diseases

Info

Publication number
MY195824A
MY195824A MYPI2017702737A MYPI2017702737A MY195824A MY 195824 A MY195824 A MY 195824A MY PI2017702737 A MYPI2017702737 A MY PI2017702737A MY PI2017702737 A MYPI2017702737 A MY PI2017702737A MY 195824 A MY195824 A MY 195824A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
gastrointestinal diseases
treating gastrointestinal
sucralfate
ranitidine
Prior art date
Application number
MYPI2017702737A
Other languages
English (en)
Inventor
Young Ho Jo
Jun Woo Lee
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY195824(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MY195824A publication Critical patent/MY195824A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/245Bismuth; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2017702737A 2015-01-30 2016-01-28 A Pharmaceutical Composition for Treating Gastrointestinal Diseases MY195824A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (ko) 2015-01-30 2015-10-22 위장질환 치료용 의약 조성물
PCT/KR2016/000935 WO2016122226A2 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases

Publications (1)

Publication Number Publication Date
MY195824A true MY195824A (en) 2023-02-22

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017702737A MY195824A (en) 2015-01-30 2016-01-28 A Pharmaceutical Composition for Treating Gastrointestinal Diseases

Country Status (19)

Country Link
EP (1) EP3250199A4 (es)
JP (1) JP6419347B2 (es)
KR (2) KR101583452B1 (es)
CN (1) CN107205947B (es)
AR (1) AR105413A1 (es)
CL (1) CL2017001680A1 (es)
CO (1) CO2017006222A2 (es)
EA (1) EA032385B9 (es)
EC (1) ECSP17038599A (es)
GE (2) GEP20196941B (es)
MA (1) MA41432A (es)
MX (1) MX375765B (es)
MY (1) MY195824A (es)
PE (1) PE20171340A1 (es)
PH (1) PH12017550051A1 (es)
SA (1) SA517382016B1 (es)
TW (1) TWI635859B (es)
UA (1) UA116517C2 (es)
WO (1) WO2016122226A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (ko) 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
KR102286499B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3874917T2 (de) * 1987-03-09 1993-03-04 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (ko) * 1992-01-22 1997-04-23 주식회사 대웅제약 위장질환 치료용 의약 조성물
CN1081921C (zh) * 1994-04-26 2002-04-03 中外制药株式会社 硫糖铝的熔融造粒制剂及其制造方法
JPH0879097A (ja) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd 携帯無線機
KR970006083A (ko) 1995-07-06 1997-02-19 한승준 자동차용 카울부의 와이어 고정장치 취부구조
WO1999010000A1 (en) * 1997-08-25 1999-03-04 The Procter & Gamble Company Combined preparations for treating upper gastrointestinal tract distress
WO2000078307A1 (en) * 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
KR101617054B1 (ko) * 2008-07-01 2016-04-29 라이온 가부시키가이샤 고형내복제제
KR20110105223A (ko) * 2010-03-18 2011-09-26 일양약품주식회사 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) * 2012-12-05 2014-06-13 (주)한국파비스제약 경구용 위장질환 치료를 위한 정제

Also Published As

Publication number Publication date
EA032385B1 (ru) 2019-05-31
EP3250199A2 (en) 2017-12-06
MX2017007567A (es) 2017-10-19
BR112017013857A2 (pt) 2018-02-27
KR101583452B9 (ko) 2022-05-02
JP6419347B2 (ja) 2018-11-07
CO2017006222A2 (es) 2017-09-20
CL2017001680A1 (es) 2018-01-12
MX375765B (es) 2025-03-07
SA517382016B1 (ar) 2021-03-18
EA201791458A1 (ru) 2017-11-30
EP3250199A4 (en) 2018-08-08
PE20171340A1 (es) 2017-09-13
KR20160094268A (ko) 2016-08-09
PH12017550051A1 (en) 2018-01-29
JP2018503672A (ja) 2018-02-08
TWI635859B (zh) 2018-09-21
GEP20186941B (en) 2019-01-10
GEAP201814551A (en) 2018-08-27
KR101583452B1 (ko) 2016-01-11
MA41432A (fr) 2017-12-05
CN107205947B (zh) 2020-05-22
TW201639559A (zh) 2016-11-16
WO2016122226A2 (en) 2016-08-04
UA116517C2 (uk) 2018-03-26
AR105413A1 (es) 2017-10-04
ECSP17038599A (es) 2017-09-29
EA032385B9 (ru) 2019-07-31
WO2016122226A3 (en) 2016-09-15
CN107205947A (zh) 2017-09-26
GEP20196941B (en) 2019-01-10

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
SG11202106160WA (en) Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient
PH12020550341A1 (en) Niraparib formulations
WO2014147611A8 (en) Quinolines derivatives as novel anticancer agents
ZA201707096B (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
IL261196A (en) A pharmaceutical preparation for cancer, containing a polyphenol compound as an active ingredient
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
EP3279210A4 (en) Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient
PT3604304T (pt) Composto derivado de pirrolo-piridina, método para a sua preparação e composição farmacêutica que o contém como substância ativa para prevenção ou tratamento de doenças relacionadas com proteína quinase
WO2015001541A3 (en) Pharmaceutical film composition
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
EP3909597A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH OLIGOPEPTIDE AS THE ACTIVE SUBSTANCE
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
PH12017550051A1 (en) A pharmaceutical composition for treating gastrointestinal diseases
EP3795170A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING CCN5 USED AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASE
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
PH12019500024A1 (en) Pharmaceutical compositions
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
HK1233927A1 (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
HK40005616A (en) Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
GR1008380B (el) Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου